Investors panicked sending shares of Nevro Corp. plummeting by about one-third on July 24 from about $60 to less than $40 as they sought to understand the implications of the latest news in ongoing patent litigation between Nevro and pain stimulation competitor Boston Scientific Corp. But in early trading on July 25, Wall Street gave back all of that roughly $500 million in market cap, as Nevro rebounded back up to a valuation of about $1.8 billion. These gyrations occurred around a Northern California District Court ruling that found that six method claims in three Nevro patents were valid, but that Boston Scientific currently is not infringing upon them. Read More
